Five-Year Study Outcomes of the NuVasive Simplify Cervical Disc were Presented at the North American Spine Society 38th Annual Meeting
24 Octubre 2023 - 6:00AM
Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal
solutions company, presented five-year outcomes from the NuVasive
Simplify Cervical Disc study at the North American Spine Society
(NASS) 38th Annual Meeting. The study demonstrates positive,
long-term clinical outcomes, a high rate of overall composite
success at 60 months, and statistical superiority to anterior
cervical discectomy fusion (ACDF) procedural outcomes.
“Having clinically backed, long-term data for the Simplify
Cervical Disc validates the promising clinical data we saw Simplify
having at the two-year mark,” said Kyle Malone, senior vice
president, Scientific Affairs of Globus Medical. “We will continue
to innovate within the cervical spine segment providing
industry-leading, procedural solutions clinically designed to
deliver better outcomes for patients.”
The five-year Simplify Cervical Disc study* found:
- Simplify Cervical Disc was statistically superior to the ACDF
control in terms of overall composite success at five years,
- Statistically significant postoperative improvements in neck
disability index (NDI) and visual analog scale (VAS) (combined neck
and arm pain) found at two years were maintained through five
years, with the Simplify Cervical Disc group having significantly
lower NDI and VAS scores at five years when compared to the ACDF
control,
- Average disc height and flexion/extension range of motion
increased postoperatively in the Simplify Disc group and remained
above preoperative levels throughout follow-up, and
- No device failures were reported in the Simplify Disc
group.
Dr. Pierce Nunley of the Spine Institute of Louisiana expressed
his enthusiasm about the durability of the positive outcomes
observed at 24 months. He stated, "I am eager to witness the
continued success of these results beyond the 60-month mark. This
study further reinforces that Simplify is an outstanding
motion-preserving solution with enduring clinical advantages over
ACDF."
*Data on file.
Simplify Cervical Disc is not yet available in all countries.
Please refer to the Simplify Disc IFU and Patient Labeling for
important product information, including but not limited to,
Indications, Contraindications, Warnings, Precautions, Risks and
Potential Adverse Effects. The IFU and Patient Labeling can be
found here.
About Globus Medical, Inc.Globus Medical is
committed to providing innovative technologies and industry-leading
clinical support to help surgeons and healthcare providers deliver
better care around the globe. The Company provides one of the most
comprehensive offerings of musculoskeletal solutions and enabling
technologies to impact the care continuum, now including the
procedurally integrated portfolio of NuVasive. The Company’s
employees are relentlessly focused on advancing patient care. For
more information, please visit www.globusmedical.com/uniting.
Safe Harbor Statements
All statements included in this press release other than
statements of historical fact are forward-looking statements and
may be identified by their use of words such as “believe,” “may,”
“might,” “could,” “will,” “aim,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “plan” and other similar terms.
These forward-looking statements are based on our current
assumptions, expectations and estimates of future events and
trends. Forward-looking statements are only predictions and are
subject to many risks, uncertainties and other factors that may
affect our businesses and operations and could cause actual results
to differ materially from those predicted. These risks and
uncertainties include, but are not limited to, the risks and
costs associated with the integration of, and the ability of Globus
Medical and NuVasive to integrate, their businesses successfully
and to achieve anticipated synergies, health epidemics, pandemics
and similar outbreaks, including the COVID-19
pandemic, factors affecting our quarterly results, our ability
to manage our growth, our ability to sustain
our profitability, demand for our products, our ability to
compete successfully (including without limitation our ability to
convince surgeons to use our products and our ability to attract
and retain sales and other personnel), our ability to rapidly
develop and introduce new products, our ability to develop and
execute on successful business strategies, our ability to comply
with laws and regulations that are or may
become applicable to our businesses, our ability to safeguard
our intellectual property, our success in defending legal
proceedings brought against us, trends in the medical device
industry, general economic conditions, and other risks. For a
discussion of these and other risks, uncertainties and other
factors that could affect our results, you should refer to the
disclosure contained in our most recent annual report on Form 10-K
filed with the Securities and Exchange Commission, including the
sections labeled “Risk Factors” and “Cautionary Note Concerning
Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and
other filings with the Securities and Exchange Commission. These
documents are available at www.sec.gov. Moreover, we operate
in an evolving environment. New risk factors and uncertainties
emerge from time to time and it is not possible for us to predict
all risk factors and uncertainties, nor can we assess the impact of
all factors on our business or the extent to which any
factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Given these risks and uncertainties, readers are
cautioned not to place undue reliance on any forward-looking
statements. Forward-looking statements contained in this press
release speak only as of the date of this press release. We
undertake no obligation to update any forward-looking statements as
a result of new information, events or circumstances or other
factors arising or coming to our attention after the date
hereof.
Investor contact:Brian
Kearns610-930-1800investors@globusmedical.com
Media contact:Melanie
Ordoñez858-722-3899media@globusmedical.com
Globus Medical (NYSE:GMED)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Globus Medical (NYSE:GMED)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024